Evaluating Ultrason Derived Fat Fraction for Liver Disease
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
University Hospital, Angers · NCT06080386
This study is trying to see if a new ultrasound method for measuring fat in the liver works as well as MRI for people with Non Alcoholic Fatty Liver Disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers (other gov) |
| Locations | 1 site (Angers) |
| Trial ID | NCT06080386 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the performance of Ultrason Derived Fat Fraction (UDFF) in comparison to MRI for quantifying fat in the liver of patients with Non Alcoholic Fatty Liver Disease (NAFLD). It includes patients who have undergone both hepatic ultrasound with UDFF measurements and MRI with steatosis quantification between January 2022 and September 2023. The study will analyze the accuracy and reliability of UDFF as a non-invasive method for evaluating liver fat content.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Non Alcoholic Fatty Liver Disease who have had both ultrasound and MRI performed within the specified timeframe.
Not a fit: Patients with chronic liver diseases of different etiologies, decompensated cirrhosis, or hepatocellular carcinoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accessible and cost-effective method for diagnosing and monitoring Non Alcoholic Fatty Liver Disease.
How similar studies have performed: While there may be existing studies on liver fat quantification, the specific evaluation of UDFF against MRI in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients who had hepatic ultrasound with available UDFF measurements and hepatic MRI (with steatosis quantification sequences) between 01/01/2022 and 31/09/2023 may be included. Exclusion Criteria: * chronic liver disease with a different etiology other than NAFL/NASH or mixed (hepatitis B or C, hemochromatosis, autoimmune hepatitis, Wilson's disease, cholestasic disease, alpha 1 antitrypsin deficiency), * decompensated cirrhosis (ascites, jaundice, encephalopathy, rupture of esophageal varices), * hepatocellular carcinoma. * opposition to the use of its data
Where this trial is running
Angers
- Angers university hospital — Angers, France (RECRUITING)
Study contacts
- Study coordinator: Christophe Aubé
- Email: chaube@chu-angers.fr
- Phone: +33 2 41 35 42 81
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non Alcoholic Fatty Liver Disease